Navigation Links
Dan Broderick Joins Prolog Ventures as Partner

ST. LOUIS, Sept. 12 /PRNewswire/ -- Prolog Ventures, a venture capital firm specializing in life science investments, today announced that Dan Broderick has joined the firm as its fourth partner. Broderick brings more than 20 years of experience in early-stage investing, venture fund management, and technology commercialization.

Before coming to Prolog, Broderick was a managing director at Mason Wells in Milwaukee, WI, where he served on its board of directors and management committee and managed the Mason Wells Biomedical Fund -- the firm's first venture capital fund. Prior to this, he spent 18 years at the Mayo Clinic in Rochester, MN, where he served as director of technology commercialization for 12 years and co-launched the clinic's corporate venture capital fund.

"Dan's extensive industry experience and deal flow connections further strengthen Prolog's expertise in early-stage life science investing," said Ilya Nykin, managing director of Prolog. "He was involved in the creation, financing, and growth of more than 20 venture-backed companies in Prolog's core areas of focus, most of them early-stage. Having Dan on Prolog's team is a great boost to our mission of translating life science breakthroughs into successful ventures."

Broderick's professional accomplishments have prompted a number of prominent industry boards and advisory panels to seek his involvement. He is a member of the board of directors of the National Venture Capital Association and the chair of its Research Committee; a trustee of both the Medical College of Wisconsin and the University of Wisconsin-Milwaukee Research Foundations; a member of the University of Minnesota Business Development Advisory Board; and a charter member of the venture capital advisory board of BioGenerator, a St. Louis nonprofit seed-capital investment fund.

"Not only is Dan an astute investor, but he is also a long-time colleague. We have an excellent track record of working together," said Greg Johnson, managing director of Prolog. "I met Dan 15 years ago, and over the years, we've collaborated on a number of investment opportunities. Our relationship expanded further in 2002 when we co-founded the Mid America Healthcare Investor Network (MHIN), an organization of more than 50 venture capital funds that focus on life science opportunities." MHIN is now recognized as one of the most active and productive venture capital associations in the country.

It was through MHIN that Broderick developed a close rapport with Prolog's other partners -- Ilya Nykin and Brian Clevinger. After Broderick's fund invested in ZyStor Therapeutics, one of the most promising ventures in Prolog's portfolio, he joined Clevinger on the company's board of directors. The two also have served together at several industry organizations including BioGenerator, InvestMidwest, and BIO Mid-America Venture Forum.

"I was attracted to Prolog because it has one of the most innovative and effective investment teams in the venture capital business," said Broderick. "I especially admire this firm for being committed since inception to balancing traditional healthcare investing with focused and resourceful pursuit of opportunities in emerging areas of life science. I am convinced this investment approach is the wave of the future and am excited to help the firm build on its early leadership position."

Prolog is a venture capital firm specializing in life science investing. Since its launch in 2001, Prolog has financed more than 20 early-stage companies. The firm is managed by a team of professionals with extensive experience as both investors and entrepreneurs. Prolog focuses on traditional healthcare opportunities as well as emerging areas - such as nutrition, wellness, plant science, and enabling platforms - in which it has built one of the largest portfolios in the country. For more information, visit

SOURCE Prolog Ventures
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Visions: Broderick says Wisconsin should be in top third in venture capital
2. Chemical-petroleum executive joins Virent Energy board
3. Schneider National exec joins TrafficCast board
4. Doyle joins governors in support of stem cell bill
5. Genomics researcher Hood joins NimbleGen board
6. Fergus joins Baird Venture Partners, Caden Bio
7. Meier joins Broadlook Technologies as COO
8. Prodesse joins forces with Invitrogen
9. Wisconsin joins price-fixing suit vs. D-RAM makers
10. Napier joins board of Third Wave Technologies
11. Schmidt rejoins Renaissance Learning
Post Your Comments:
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software ... events in five states to develop and pitch their BIG ideas to improve health ... state are competing for votes to win the title of SAP's Teen Innovator, an ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
(Date:11/24/2015)... SAN FRANCISCO , Nov. 24, 2015 /PRNewswire/ ... today announced that Emily Leproust, Ph.D., Twist Bioscience ... Piper Jaffray Healthcare Conference on December 1, 2015 ... Palace Hotel in New York City. ... . Twist Bioscience is on ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris , qui ... Paris , qui s,est tenu du ... leader de l,innovation biométrique, a inventé le premier scanner ... sur la même surface de balayage. Jusqu,ici, deux scanners ... les empreintes digitales. Désormais, un seul scanner est en ...
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
Breaking Biology News(10 mins):